Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Anuh Pharma Ltd. Share Price
Day's Range
Low
₹89.80
High
₹92.00
Price Summary
| Previous Close | ₹90.42 |
|---|---|
| Day's Range | ₹89.80 - ₹92.00 |
| Open | ₹90.00 |
| 52 Week Range | ₹67.00 - ₹99.50 |
| Volume | 79,711 |
| Market Cap | ₹0.00 |
| Previous Close | ₹90.00 |
|---|---|
| Day's Range | ₹89.94 - ₹92.40 |
| Open | ₹90.00 |
| 52 Week Range | ₹66.72 - ₹99.50 |
| Volume | 24,127 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 72.07 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.66 |
| Price/Earning (TTM) | 20.49 |
| TTM EPS (₹) | 4.41 |
| P/E Ratio | 16.39 |
| Book Value(₹) | 2.49 |
| PAT Margin (%) | 5.27 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.02 |
| Trade Value ( ₹ in Lacs) | 21.71 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.66 |
| Price/Earning (TTM) | 20.49 |
| TTM EPS (₹) | 4.41 |
| P/E Ratio | 16.39 |
| Book Value(₹) | 2.49 |
| PAT Margin (%) | 5.27 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.02 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1864.79 | 6615.15 |
| Expenses | N/A | N/A |
| PBT | 109.53 | 610.05 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 83.01 | 473.52 |
About Anuh Pharma Ltd.
| Founded | 1960 |
|---|---|
| NSE Symbol | ANUHPHR |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,44,716.74 | 1,853.50 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,55,115.31 | 9,610.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,89,613.38 | 4,985.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,27,823.12 | 8,889.90 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,19,899.96 | 1,202.00 | 835.50 - 835.50 |
| Lenskart Solutions Ltd. | 1,18,325.00 | 682.80 | 0.00 - 0.00 |
| Cipla Ltd. | 1,12,875.68 | 1,397.20 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,08,116.47 | 2,001.00 | 823.10 - 823.10 |
| Mankind Pharma Ltd. | 1,02,247.25 | 2,460.00 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,00,395.34 | 1,202.80 | 1,101.00 - 1,101.00 |
No Records Found
Latest News
Caplin Point Laboratories informs about proceedings of AGM
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Caplin Point Laboratories has informed that it enclosed the brief proceedings of the 35th Annual General Meeting of the Company held on Friday, September 25, 2026, at 10.00 AM (IST), through Video Conferencing/Other Audio-Visual Means. The details of the consolidated voting results of both the remote e-voting and e-voting during the AGM on all the resolutions will be filed separately, in the format prescribed under Regulation 44 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
Vivo Bio Tech informs about closure of trading window
Rainbow Children’s Medicare informs about closure of trading window
Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Code for Prevention of Insider Trading, Rainbow Children’s Medicare has informed that the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives with effect from Thursday, October 1, 2026. The Trading Window shall re-open 48 hours after the declaration of the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026.
The above information is a part of company’s filings submitted to BSE.
Lotus Eye Hospital and Institute informs about closure of trading window
Pursuant to SEBI (PIT) Regulations, 2015 and as per the Company’s Code of Conduct for Prevention of Insider Trading, Lotus Eye Hospital and Institute has informed that the Trading Window for dealing in the equity shares of the Company by the Designated Persons & their immediate relatives shall remain closed from October 1, 2026 till the end of 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. The date of the Board Meeting for consideration and approval of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 will be intimated in the due course.
The above information is a part of company’s filings submitted to BSE.
Ajanta Pharma informs about closure of trading window
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Anuh Pharma Ltd. is ₹90.42 as of 2026-09-25.
The market capitalisation of Anuh Pharma Ltd. is ₹905.02 as of 2026-09-25.
The 1-year return of Anuh Pharma Ltd. is 5.05% as of 2026-09-25.
The P/E ratio of Anuh Pharma Ltd. is 16.39 as of 2026-09-25.
The 52-week high and low of Anuh Pharma Ltd. are ₹99.50 and ₹67.00, respectively, as of 2026-09-25.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
